| Name | Title | Contact Details |
|---|
We combine world-leading technology with our thorough understanding of how child sexual abuse material is disseminated online.
WebCreek offers nearshoring software development and IT staffing solutions. Hire top IT talent to build your custom software solutions.
We deliver the most advanced Enterprise #RPA Platform, built for business and IT. As you strive to benefit in the Automation First Era, your digital transformation accelerates here. • More than 2,750 enterprise customers and government agencies use UiPath`s Enterprise RPA platform to rapidly deploy software robots that perfectly emulate and execute repetitive processes, boosting business productivity, ensuring compliance and enhancing customer experience across back-office and front-office operations. • Our technology is used by thousands of companies particularly in document management, contact center, healthcare, finance and accounting, human resources, and supply chains and to address major technical challenges, including data extraction and migration, process automation, application integration and business process outsourcing. • We encourage the best minds to contribute and create the next leap in RPA. More than 300,000 developers of all ranks are building upon the UiPath Community Edition, and to support this growing pool of talent, we brought UiPath Academy to the world as the first open online training and certification platform dedicated to RPA users. More than 200,000 users spanning all continents have enrolled in at least one of our online courses since its launch in April 2017. Based in New York City, UiPath`s presence extends to 31 offices across 19 countries throughout North America, Europe, and Asia.
🎮 | An esports solution for true digital item ownership ⛓ | Blockchain for every gamer Est. February 2014 #gamecredits $game
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.